Geron Corp

GERNNASDAQ • USD
1.23 USD
↗ 0.02 (1.24%)🟢LIVE (AS OF 02:47 PM EDT)
🟢Market: OPEN

Geron Corp (GERN) trades at $1.23 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place GERN at a fair price relative to peers.

Technical & fundamental data as of Oct 5, 2026.

Open?$1.20
High?$1.25
Low?$1.19
Prev. Close?$1.21
Volume?3.0M
Avg. Volume?10.8M
VWAP?$1.22
Rel. Volume?0.28x
Bid / Ask
Bid?$1.22 × 25.1K
Ask?$1.23 × 24.9K
Spread?$0.01
Midpoint?$1.23
Valuation & Ratios
Market Cap?777.4M
Shares Out?642.5M
Float?626.7M
Float %?97.6%
P/E Ratio?N/A
P/B Ratio?3.56
EPS?-$0.11
Dividend?0.00%
Ex-Dividend?N/A
RelatedALKS
News
Profile
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Employees
258
Market Cap
777.4M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
1996-07-31
Address
919 EAST HILLSDALE BOULEVARD
FOSTER CITY, CA 94404
Phone: (650) 473-7700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
20
Short Sent.?
54
Piotroski F-Score?2/9Weak
Altman Z-Score?-2.48Distress
Confidence?61%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?13.18%High
Short Interest?82.6M
Days to Cover?6.7
Free Float626.7M
Avg Daily Volume12.3M
Settlement Date2026-09-15
Financial Health
Current Ratio?6.92Strong
Quick Ratio?5.16Strong
Cash Ratio?0.89Adequate
Debt/Equity?1.14Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
75/100
P/E?
N/A▾
P/B?
Peers
100
S&P
48
3.56FAIR▾
P/S?
Peers
100
S&P
40
3.80FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
-27.7CHEAP▾
EV/Sales?
Peers
100
S&P
38
4.72FAIR▾
Returns & Efficiency
ROE?
Peers
50
S&P
6
-30.9%WEAK▾
ROA?
Peers
50
S&P
3
-13.0%WEAK▾
Cash Flow & Enterprise
FCF?$-114762000
Enterprise Value?$964.5M
Fundamentals ratios updated end of day